International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
CD20 monoclonal antibody‑rituximab for the treatment of diffuse alveolar hemorrhage in children (Review)
Diffuse alveolar hemorrhage (DAH) is a rare life‑threatening pulmonary disorder in children, characterized by cough, hemoptysis and dyspnea. The pathogenesis is not fully understood, posing notable challenges for clinical diagnosis and management. Recent advances have gradually revealed potential etiologies and associated immune mechanisms, driving the development and application of novel therapies. The present review aimed to summarize the current understanding of the etiology, diagnostic approaches and therapeutic strategies for pediatric DAH, with a focus on the emerging role of the CD20 monoclonal antibody rituximab, and highlighted clinical evidence supporting its use in immune‑related DAH. The present review aimed to provide a foundation for further research and optimize clinical decision‑making.